| Name | Title | Contact Details |
|---|
Cagent Vascular is leading the way for next generation technology for vessel dilatation.
Total Contact is a Germantown, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Heru Inc. (www.SeeHeru.com) has developed patented autonomous AI-powered vision diagnostics and augmentation software for commercially available AR/VR devices. This technology exceeds traditional standards of care in clinical equivalence, usability, cost, size and portability. Heru is the only cross-platform solution that can autonomously diagnose vision defects and customize individual vision augmentation based on the user`s unique vision defects.
At Olympus, we put a lot of good back into the world, and what we do, really matters. We are committed to making people`s lives healthier, safer and more fulfilling every day by crafting innovative optical and digital solutions in medical technologies; life sciences; industrial solutions; and cameras and audio products. Everything we do at Olympus is a reflection of our vision, and everyone here helps to make it a reality. We view our relationship with and commitment to our employees with the same passion. Everything we do at Olympus is a reflection of our purpose and everyone here helps to make it a reality. We`re invested in our employees, great ideas, and how they impact the communities around us. We see the world through multiple lenses and come together to find the right answers; the best solutions. Olympus Corporation of the Americas (OCA)—a wholly owned subsidiary of Olympus Corporation in Tokyo, Japan—is headquartered in Center Valley, Pennsylvania, and employs more than 5,300 people at our locations throughout North and South America. Join us!
Founded in 2011, Sight Sciences develops and commercializes intelligently designed and engineered products that target the underlying causes of the world`s most prevalent eye diseases. The company`s surgical glaucoma product portfolio features the OMNI Surgical System, a dually indicated MIGS device that facilitates the performance of both ab interno trabeculotomy and transluminal viscoelastic delivery. Using proprietary multi-modal functionality, OMNI allows surgeons to target all three sources of resistance in the conventional outflow pathway (trabecular meshwork, Schlemm`s canal and collector channels) with a single device and single corneal incision. The company`s non-surgical dry eye product portfolio consists of the TearCare for ophthalmologists and optometrists. TearCare is a software-controlled, wearable, therapeutic eyelid technology designed to melt and clear obstructions of the meibomian glands within the eyelids. Leveraging the full functionality of the blinking eye, proprietary SmartLid™ technology is designed to conform to all eyelid anatomies and achieve therapeutic meibum melting temperatures at the tarsal conjunctiva thereby clearing meibomian gland obstructions while sparing the cornea. Improved meibum production results in a higher quality lipid layer and higher quality tears.